Goldman Sachs
NVCT icon

Goldman Sachs’s Nuvectis Pharma NVCT Stock Holding History

Goldman Sachs’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Buy
41,124
+14,621
+55% +$125K ﹤0.01% 5868
2025
Q4 		$200K Sell
26,503
-18,660
-41% -$122K ﹤0.01% 6043
2025
Q3 		$272K Buy
+45,163
New +$310K ﹤0.01% 5809
2025
Q2 		– Sell
-45,608
Closed -$446K – 6321
2025
Q1 		$446K Buy
+45,608
New +$328K ﹤0.01% 5253
2024
Q3 		– Sell
-61,570
Closed -$390K – 5999
2024
Q2 		$390K Buy
+61,570
New +$418K ﹤0.01% 4963

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs's NVCT Position: Q1 2026 in Review

Goldman Sachs increased its Nuvectis Pharma (NVCT) stake by 55% in Q1 2026, buying an estimated $125K and bringing the position to 41,124 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #5868.

Goldman Sachs first reported a position in NVCT in Q2 2024 and has held it in 5 quarters since. The position peaked at $446K in Q1 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Goldman Sachs held 41,124 shares of Nuvectis Pharma worth $318K as of Q1 2026.
  • Goldman Sachs bought 14,621 Nuvectis Pharma shares in Q1 2026, an estimated $125K.
  • Nuvectis Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5868 holding.
  • Goldman Sachs first reported a position in Nuvectis Pharma in Q2 2024 and has held it in 5 quarters since.
  • Goldman Sachs's Nuvectis Pharma position peaked at $446K in Q1 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.